Halozyme Therapeutics (HALO) Tops Q2 EPS by 4c, Revenues Miss; Maintains FY19 Revenue Guidance Above Consensus
Tweet Send to a Friend
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of ($0.10), $0.04 better than the analyst estimate of ($0.14). Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
